Prolonged-Use of Inhaled Gaseous Nitric Oxide (gNO) for Adult With Non-Tuberculous Mycobacteria Infection

Phase 2

Completed

• Conditions: Non-Tuberculous Mycobacterial Pneumonia
• Interventions: Drug: Nitric Oxide gas at 160ppm

• Registration Number: NCT03473314
• Lead Sponsor: University of British Columbia

Brief Summary

An open labeled Study (NCT03331445) is demonstrating encouraging safety and efficacy results for most subjects receiving 160ppm nitric oxide gas (gNO) for treatment of non-tuberculous mycobacteria (NTM) over a 15 day treatment regimen. In one subject, who had a reduction in sputum culture concentration of Bacterium bolletii from plus 3 to plus 1 corresponding to a 2-3 log10 cfu/gm reduction during the treatment, the one-week post treatment follow-up sputum culture had increased to plus 2. It is hypothesized that a longer treatment period may be necessary to fully eradicate NTM from the sputum culture in chronic lung disease. This study will extend the period of gNO exposure for a prolonged period of time (3 months) to attempt to fully eradicate the NTM in this single subject. This study will transition from the medical clinic to supervised delivery in the patient's home environment.

Detailed Description

Primary Objective: Determine the efficacy of prolonged delivery of inhaled nitric oxide to treat an adult patient with pulmonary NTM Primary Endpoint: Eradication of NTM growth in sputum cultures. Efficacy will be assessed by the antimicrobial effect of inhaled NO on the density of NTM species and other microorganisms in the sputum.

• as confirmed by measurement of semi-quantitative culture sputum growth which has been verified with serial dilution technique on Day 7, 14, 21 and every 21 days thereafter for 90 days as compared to pre-treatment baseline sputum culture.

Secondary Objective(s): Determine the safety \& efficacy of inhaled nitric oxide

Secondary Endpoint(s):

1. Safety

• as evaluated by the number of unanticipated adverse events during home delivery in clinical labs (hematology, coagulation, and serum chemistries); in vitals; in inspired concentration of NO, O2 and NO2 delivered to subject and; in methemoglobin and oxygen saturation levels.

2. Efficacy

* as determined by improvement in lung function as measured by spirometry, endurance as measured by six minute walk-test and quality of life as determined by self-reporting quality of life questionnaire (CFQ-R) on Day 7, 14, 21 and every 21 days thereafter for 90 days as compared to pre-treatment baseline data.

* as assessed by recurrence of NTM in sputum as confirmed by measurement of semi-quantitative culture sputum growth on Day 30 and 60 post treatment.

Study Timeline

• Study Start: 2018-03-09
• Study First Submitted: 2018-03-14
• Study First Submitted QC: 2018-03-20
• Study First Posted: 2018-03-22
• Status Verified: 2020-07
• Primary Completion: 2020-07-11
• Study Completion: 2020-07-21
• Last Update Submitted: 2020-07-27
• Last Update Posted: 2020-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• Written informed consent.
• Has been previously diagnosed with NTM. [NTM defined as positive culture(s) of at least one species of Mycobacterium avium Complex (MAC) or Mycobacterium abscessus Complex (MABSC)]
• Has been previously treated with gNO for 15 days without complete eradication of NTM but with a decrease of at least 1-2 points on cultures.
• Male or female ≥19 years of age.
• Female not pregnant at time of study.
• Oxygen saturation on room air ≥92% at screening. (able to breathe without supplemental oxygen for 60 minutes)
• Non-smoker for at least 6 months prior to screening and agrees not to smoke during the study.
• Willing and able to comply with the treatment schedule and procedures.

Read More

Exclusion Criteria

• History of frequent epistaxis (>1 episode/month)

• History of reactive pulmonary vascular hypertension

• Methemoglobin >3% at screening

• Liver function insufficiency aspartate aminotransferase/alanine aminotransferase (AST/ALT) >3 of normal values)

• Hemoglobin <10 g/dl

• Thrombocytopenia (platelet count <100,000/mm3) at screening

• Prothrombin time international ratio (INR) > 1.3 at screening

• On supplemental oxygen during gNO treatment (SaO2 < 90% for 50 minutes while resting in a chair).

• For women of child bearing potential:

  1. positive pregnancy test at screening or
  2. lactating or
  3. unwilling to practice a medically acceptable form of contraception from screening to Day 36 (acceptable forms of contraception: abstinence, hormonal birth control, intrauterine device, or barrier method plus a spermicidal agent)

• Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Nitric Oxide gas at 160ppm	Nitric Oxide gas at 160ppm	Nitric Oxide 160ppm for 50-80 minutes two -three times a day for 365 days

Primary Outcome Measures

Name	Time	Method
Eradication of NTM in sputum	365 days	The primary efficacy variable for this study is eradication of recovered NTM organisms in sputum colony forming unit (CFU) g (log 10) from baseline. Eradication will be defined as two negative sputum cultures post nitric oxide gas treatment over 60 days.

Secondary Outcome Measures

Name	Time	Method
Mean change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) scores for each domain from baseline	365 days	Clinical Measurement of Mean change in CFQ-R scores for each domain from baseline. Each domain measure the magnitude of severity for each of the 8 items. Respondents score each item using a 5-point likert scale ranging from 0 (no symptom) to 4 (the highest magnitude of severity). For item 1 (difficult to breathe), item 2 (feel feverish), item 3 (tired), item 6 (mucus), and item 7 (chest tightness) the response options are: 0=No symptom, 1=a little, 2=somewhat, 3=a good deal, 4=a great deal. For item 4 (chills/sweats), item 5 (cough), and item 8 (wheezing) the response options are: 0=no symptom, 1=slightly, 2=moderately, 3=very, 4=extremely.
Nitric oxide delivery effect on systemic methemoglobin levels in home delivery	365 days	Safety measured as evaluated by the number of unanticipated adverse events in pulseoixmetric arterial methemoglobin percent levels during nitric oxide delivery.
Mean absolute change in forced expiratory volume at one second (FEV1)% from baseline.	365 days	Clinical Measurement of Mean absolute change in FEV1% from baseline to Day 365 (within group test).
Nitric oxide delivery effect on key physiologic vital signs in home delivery	365 days	Safety measured as evaluated by the number of unanticipated adverse events in vitals signs (blood pressure, respiratory rate) and oxygen saturation levels during NO delivery.
Mean change in distance walked in the six-minute walk test from baseline	365 days	Clinical Measurement of Mean change in distance walked in the six-minute walk test from baseline.
Nitric oxide effect on delivery parameter concentrations in home delivery	365 days	Safety measured as evaluated by the number of unanticipated adverse events with inspired concentration of nitric oxide (NO), oxygen (O2) and nitrogen dioxide (NO2) delivered to subject.
Recurrence of NTM in sputum culture post NTM eradication.	30 and 60 days post NTM eradication	Measurement of recovered NTM organisms in sputum colony forming unit (CFU) g (log 10) post eradication. Eradication will be defined as two negative sputum cultures post nitric oxide gas treatment over 60 days.
Nitric oxide delivery effect on clinical values in home delivery	365 days	Safety measured as evaluated by the number of unanticipated adverse events in clinical labs (hematology, coagulation, and serum chemistries).

Trial Locations

Locations (1)

Gordon Leslie Diamond Health Care Centre; 🇨🇦 Vancouver, British Columbia, Canada